Dahl 2025 — Amycretin GLP-1 and Amylin Agonist Phase 1

The Lancet

Katrine Dahl, et al.

Summary

Subcutaneous amycretin showed a safety and tolerability profile consistent with GLP-1 and amylin agonism and produced large early body-weight reductions.

Study Details

Study Design

Phase 1 randomized placebo-controlled trial

Indication

Overweight or obesity

Intervention

Once-weekly subcutaneous amycretin up to 60 mg

Species

Human

Risk of Bias Assessment

Early phase; sponsor-funded